Cipla Limited has entered into an exclusive Supply and Marketing Agreement with Pfizer Products India Private Limited and Pfizer Limited for a period of 5 years. This agreement grants Cipla the sole rights to market, distribute, and sell four key Pfizer brands in India: Corex Dx and Corex LS (cough syrups), Dolonex (a non-steroidal anti-inflammatory drug), Neksium (a proton pump inhibitor), and Dalacin C (an oral antibiotic). Under the terms of the agreement, Pfizer will continue to manufacture, source, and supply these medicines to Cipla for the Indian market. The partnership aims to leverage Cipla's extensive customer understanding, distribution reach, and network to ensure wider availability of these trusted therapies across India. Both companies expressed enthusiasm for the collaboration, highlighting their shared commitment to meeting patient needs and advancing healthcare outcomes. This marks the first such partnership between Pfizer and Cipla in India. The agreement does not involve any upfront consideration paid or received, with other commercial terms to be agreed upon by the parties. The rationale behind the agreement is to enhance the reach and depth of these medicines within the Indian market.